Qualitative investigation into a wearable system for chronic obstructive pulmonary disease: the stakeholders' perspective by Kayyali, Reem et al.
BMJ Open Diab Res Care 2020;0:e001122. doi:10.1136/bmjdrc-2019-001122
Open access 
1
Predicting the risk of future diabetic 
foot ulcer occurrence: a prospective 
cohort study of patients with diabetes 
in Tanzania
Roozbeh Naemi   ,1 Nachiappan Chockalingam   ,1 Janet K Lutale,2 
Zulfiqarali G Abbas2,3
1School of Life Sciences 
and Education, Staffordshire 
University, Stoke- on- Trent, UK
2Muhimbili University of Health 
and Allied Sciences, Dar es 
Salaam, Tanzania
3Abbas Medical Centre, Dar es 
Salaam, Tanzania
Correspondence to
Professor Roozbeh Naemi;  
 r. naemi@ staffs. ac. uk
To cite: Naemi R, 
Chockalingam N, Lutale JK, 
et al. Predicting the risk of 
future diabetic foot ulcer 
occurrence: a prospective 
cohort study of patients with 
diabetes in Tanzania. BMJ 
Open Diab Res Care Published 
Online First: [please include 
Day Month Year]. doi:10.1136/
bmjdrc-2019-001122
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjdrc- 2019- 001122).
Received 18 December 2019
Revised 28 February 2020
Accepted 24 March 2020
Original research
Pathophysiology/Complications
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
Significance of this study
What is already known about this subject?
 ► Insensitivity to a 10 g monofilament or one absent 
pedal pulse was reported to be adequate to identify 
patients with moderate risk of foot ulceration, while 
history of diabetic foot ulcer (DFU) or lower- extremity 
amputations was found to allow identifying those at 
high risk of developing DFU.
What are the new findings?
 ► Presence of dry skin or nail ingrowth increases the 
likelihood of future incident of DFU by more than four 
times.
 ► Impaired sensation to vibration, measured as vibra-
tion perception threshold, was significantly associat-
ed with increased risk of DFU.
 ► Decreased sensation to touch was associated with 
future incidents of DFU and can be used for DFU risk 
stratification.
 ► Increased tolerance thresholds to temperature stim-
uli were associated with increased likelihood of fu-
ture ulceration.
How might these results change the focus of 
research or clinical practice?
 ► Nail ingrowth and dry skin were found to be strong 
indicators for vulnerability of patients to future dia-
betic foot ulceration as presence of each showed to 
increase the ulceration risk by more than four times. 
Assessment of neuropathy in relation to both small 
and large fiber impairment needs to be considered 
for predicting the risk of diabetic foot ulceration.
AbStrAct
Objectives The aim of this study was to identify the 
parameters that predict the risk of future foot ulcer 
occurrence in patients with diabetes.
Research design and methods 1810 (male (M)/female 
(F): 1012/798) patients, with no foot ulcer at baseline, 
participated in this study. Data from a set of 28 parameters 
were collected at baseline. During follow- up, 123 (M/F: 
68/55) patients ulcerated. Survival analyses together with 
logistic regression were used to identify the parameters that 
could predict the risk of future diabetic foot ulcer occurrence.
Results A number of parameters (HR (95% CI)) including 
neuropathy (2.525 (1.680 to 3.795)); history of ulceration 
(2.796 (1.029 to 7.598)); smoking history (1.686 (1.097 to 
2.592)); presence of callus (1.474 (0.999 to 2.174)); nail 
ingrowth (5.653 (2.078 to 15.379)); foot swelling (3.345 
(1.799 to 6.218)); dry skin (1.926 (1.273 to 2.914)); limited 
ankle (1.662 (1.365 to 2.022)) and metatarsophalangeal 
(MTP) joint (2.745 (1.853 to 4.067)) ranges of motion; and 
decreased (3.141 (2.102 to 4.693)), highly decreased (5.263 
(1.266 to 21.878)), and absent (9.671 (5.179 to 18.059)) 
sensation to touch; age (1.026 (1.010 to 1.042)); vibration 
perception threshold (1.079 (1.060 to 1.099)); duration of 
diabetes (1.000 (1.000 to 1.000)); and plantar pressure at the 
first metatarsal head (1.003 (1.001 to 1.005)), temperature 
sensation (1.019 (1.004 to 1.035)) and temperature tolerance 
(1.523 (1.337 to 1.734)) thresholds to hot stimuli and blood 
sugar level (1.027 (1.006 to 1.048)) were all significantly 
associated with increased risk of ulceration. However, plantar 
pressure underneath the fifth toe (0.990 (0.983 to 0.998)) 
and temperature sensation (0.755 (0.688 to 0.829)) and 
temperature tolerance (0.668 (0.592 to 0.0754)) thresholds 
to cold stimuli showed to significantly decrease the risk of 
future ulcer occurrence. Multivariate survival model indicated 
that nail ingrowth (4.42 (1.38 to 14.07)); vibration perception 
threshold (1.07 (1.04 to 1.09)); dry skin status (4.48 (1.80 
to 11.14)); and temperature tolerance threshold to warm 
stimuli (1.001 (1.000 to 1.002)) were significant predictors 
of foot ulceration risk in the final model. The mean time to 
ulceration was significantly (p<0.05) shorter for patients with: 
dry skin (χ2=11.015), nail ingrowth (χ2=14.688), neuropathy 
(χ2=21.284), or foot swelling (χ2=16.428).
Conclusion Nail ingrowth and dry skin were found to be 
strong indicators of vulnerability of patients to diabetic 
foot ulceration. Results highlight that assessments of 
neuropathy in relation to both small and larger fiber 
impairment need to be considered for predicting the risk of 
diabetic foot ulceration.
InTROduCTIOn
With a prevalence rate of between 15% and 
34% in persons with diabetes,1 2 diabetic 
foot ulcer (DFU) is the main cause of non- 
traumatic lower limb amputation world-
wide.1 Approximately 50% of diabetic ulcers 
become infected3 and 20% of moderate or 
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severe diabetic foot infections lead to amputation.4 5 The 
presence of DFU in patient increase the risk of death 
at 5 years by 2.5 times.6 The prevalence of DFU in 
African countries is 4%–19%7 imposing heavy burden 
on health systems.8 While the clinical presentation of 
diabetic lesions in Tanzanian populations was previously 
reported,9 to decrease the socioeconomic cost associated 
with diabetic foot complications, a population- based 
DFU risk assessment tool needs to be developed that can 
identify patients vulnerable to future DFU occurrence.
There has been an abundance of studies focusing on 
the predictive factors for diabetic foot ulceration with the 
majority indicating the multifactorial nature of DFUs and 
their link to a number of different parameters. Systematic 
reviews of the literature indicated that impaired sensation, 
peripheral vascular disease indicated by ankle brachial 
index (ABI), vibration perception threshold (VPT), peak 
plantar pressure, foot deformities, and fasting blood sugar 
level were identified as risk factors for DFU.10 11 Further-
more, other easily identifiable parameters like age, dura-
tion of diabetes, height, body weight, and body mass index 
(BMI) have been associated with the risk of DFU occur-
rence.10 11
In addition, studies indicated that peak plantar pres-
sure,12 ankle range of motion,13 and hallux limitus14 were 
associated with an increased risk of DFU occurrence. 
Although impaired thermal sensation, which is clinically 
associated with small fiber neuropathy has also been 
previously linked to the presence of neuropathic DFU,15 
the value of this parameter in predicting the risk of DFU 
occurrence has not been previously established in a large 
cohort of patients.
A previous systematic review of the risk stratification 
systems for diabetic foot ulceration identified: (A) foot 
deformity, (B) peripheral neuropathy (VPT or cutaneous 
insensitivity to monofilament), (C) peripheral arterial 
disease (pulses and/or ABI), (D) previous amputation, 
(E) the presence of callus, (F) hemoglobin A1c, (G) 
tinea pedis, and (H) onychomycosis as factors that are 
commonly used to predict the risk of ulceration.10
A recent systematic review of literature and meta- 
analysis reported insensitivity to a 10 g monofilament 
or one absent pedal pulse as prognostic factors to iden-
tify patients with moderate or intermediate risk of foot 
ulceration.11 While history of DFUs or lower- extremity 
amputations was reported to be sufficient to identify 
those at high risk of developing DFU.11 Despite these, all 
reviewed studies in these systematic reviews were focused 
on western population.16 Hence there is a scarcity of 
studies which highlights the characteristics of patients 
who are vulnerable to future DFU occurrence in other 
populations. This is particularly evident for an African 
population. In addition, there is a dearth of studies in 
which a combination of foot- related and generic clinical 
parameters is investigated. Furthermore, the role of these 
parameters in identifying patients with further likelihood 
and higher risk of developing diabetic foot ulceration 
incident has not adequately been identified.
The overall aim of this study was to identify a set of 
risk factors that could be used to predict the future DFU 
occurrence in patients with diabetes from Tanzania. The 
first objective of this study is to identify the differences 
in the characteristics of patients with (against patients 
without) future DFU occurrence. The second objective 
of this study was to identify the parameters that identify 
the risk (hazard) and likelihood (odds) of future DFU 
occurrence and to propose a model that can predict the 
risk of future DFU occurrence in this group of patients.
MeTHOds
Participants
Ethical approval was granted by the local ethics committee. 
Participants were recruited from patients who attended 
the clinic between January 2011 and December 2015.
All data were collected in a specialist clinic located 
within a city. This clinic had a comprehensive outpatient 
capacity and is one of the main diabetic foot clinics in 
the Eastern, Western and Central Africa with a focus on 
foot complication as a result of diabetes. The primary 
inclusion criteria was that the patient being diagnosed 
with diabetes. The main exclusion criterion was the pres-
ence of any DFU at baseline. DFU was defined as a full- 
thickness wound involving the foot or the ankle, distal to 
and including the malleoli.
The sample size was calculated as 1584 participants 
based on the diabetic foot ulceration rate of 7% in 
diabetes population in Africa17 with alpha level of 5% 
and power of 95%. Assuming a missing data in 1 out 
of 8 participants, an additional 227 participants were 
recruited.
data collection
A set of 28 categorical and continuous parameters 
were collected from the patients during a single visit at 
baseline.
Categorical parameters
The general categorical parameters were: smoking 
(current smoker, never smoked, previous smoker), 
alcohol habits (currently drinks, never drunk, in the 
past), previous amputation, and history of ulceration 
according to protocols set by International Working 
Group on the Diabetic Foot (IWGDF).18
The foot- specific categorical parameters included: 
neuropathy and touch sensation tests. Neuropathy was 
assessed using 10 g monofilament19 on both feet at 10 
sites including hallux, third toe, fifth toe, first metatarsal 
head (MTH), third MTH, fifth MTH, lateral midfoot, 
medial midfoot, center of the hindfoot, and dorsum of 
the foot.20 The touch sensation was assessed using Ipswich 
touch test that involved lightly touching/resting the tip 
of the index finger for 1–2 s on the tips of the first, third, 
and fifth toes.21 Touch sense status was defined: normal 
as 0 (zero) insensate sites, decreased as 1–3 insensate 
sites, highly decreased as 4–5 insensate sites, and absent 
as 6 insensate sites from the total 6 sites tested.
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Foot deformity was assessed as structural abnormal-
ities in the foot such as claw/hammer toe and hallux 
valgus or prominent MTHs, status after Charcot foot, 
amputations and other foot surgery were considered 
as having foot deformity.14 Skin status was considered 
as: dry when epidermis lacks moisture or sebum, and 
normal: well- balanced skin eudermic that is neither 
too oily nor too dry .22 23 Dry skin is very common in 
patients with diabetes where the skin lacks adequate 
moisture. On visual examination dry skin looks rough, 
shows signs of itching, have flaking, scaling or peeling. 
Fine lines and crack can be seen on the skin, which 
leads to deep cracks that may bleed and ulcers. In 
addition, the skin becomes gray and ashy. Mycosis was 
considered as fungal infection in between the toes and 
macerated skin.22
Nail ingrowth was considered as in- growing toe nail 
(also known as onychocryptosis) and it was considered 
as present when the nail grows so that it cuts into one or 
both sides of the paronychium or nail bed.22 Swelling was 
considered as present when swelling of foot sufficiently 
pronounced to leave a clear imprint of the pressure 
by a finger.22 Presence of callus was also considered to 
be present based on the protocol proposed in IWGDF 
guidelines.22 Specific categorical parameters for each 
participant were defined as if these occurred on either or 
both feet for each participant.
Continuous parameters
The general continuous parameters included: age, 
weight, height, duration of diabetes, blood glucose level, 
and BMI. The foot- specific continuous parameters were: 
ankle brachial pressure index, vibration perception 
threshold (VPT), temperature sensation threshold (TST) 
and temperature tolerance threshold (TTT), and plantar 
pressures during walking. VPT was measured using 
a clinically accepted device (Neuropathy Analyser—
Vibrotherm—Dx ; Diabetik Foot Care India, Chennai, 
India) at the wrist, knee, ankle, and big toe according 
to the previous protocol.24 This device was also used to 
measure the TST and TTT to both cold/warm stimuli at: 
hallux, third toe, fifth toe, underneath the arch and heel 
according to a previous protocol.25
A plantar pressure platform (EMED, Novel, Munich, 
Germany) was used to measure average peak plantar 
pressure during the stance phases of walking at 16 sites 
(hallux, second toe, third toe, fourth toe, fifth toe, first 
MTH, second MTH, third MTH, fourth MTH, fifth MTH, 
lateral midfoot, central midfoot, medial midfoot, lateral 
hindfoot, medial hindfoot, center of the hindfoot), based 
on a previous protocol.26 The participants were asked to 
walk over the platform using a two- step protocol27 after 
completing a number of familiarization trials. The mean 
of peak pressures from three stance phases from each foot 
was calculated based on which the overall and regional 
pressures were reported.28 All specific continuous param-
eters were averaged between the left and right feet.
data analyses
All statistical tests were performed using IBM SPSSV.25.
Test of differences
Chi- square test for independence with Yates Continuity 
Correction was used to identify significant (p<0.05) associa-
tion between categorical parameters and the future occur-
rence of DFU. For two- category parameters the effect sizes 
were determined based on Phi coefficient, where 0.01, 0.3, 
and 0.5 represent small, medium, and large effect sizes, 
respectively. For three- category parameters the effect sizes 
were determined based on the value of Cramer’s V coeffi-
cient, where 0.07, 0.21, and 0.35 represent small, medium, 
and large effect sizes, respectively. For four- category param-
eters the effect sizes were determined based on Cramer’s 
V coefficient, where 0.06, 0.17, and 0.29 represent small, 
medium, and large effect sizes, respectively.
Furthermore, given the non- normal distribution of the 
data which was established through the test of normality 
(Kolmogorov- Smirnov, p<0.05), Mann- Whitney U test 
was used to assess significant (p<0.05) differences in 
continuous parameters between the patients with and 
without future ulceration. Mann- Whitney U test identi-
fies the effect size based on the values of r=z/(N1+N2)0.5 
where 0.1, 0.3, and 0.5 represent small, medium, and 
larger effect sizes, respectively.
Assessment of the contribution of parameters to predicting the 
survival (ulcer-free status) and occurrence (incident) of DFUs
Cox univariate regression was used to assess the contri-
bution of each of the categorical and continuous param-
eters to predicting the risk of DFU occurrence (HR). In 
addition, Kaplan- Meier survival analyses were used to 
compare the differences in survival time (ulcer- free time) 
for categorical parameters. Univariate logistic regression 
was also used to assess if each of the parameters contrib-
uted to predicting future DFU likelihood (OR) indepen-
dent of the time of occurrence.
The logistic regression has the capability to identify the 
parameters that contribute to predicting the likelihood 
of ulcer occurrence. This is independent of the time 
of occurrence and is reported as ORs. This ratio indi-
cates the likelihood of ulcer occurrence. On the other 
hand, the survival analyses identify the parameters that 
contribute to predicting the ulcer occurrence consid-
ering the time to occurrence. This analysis includes the 
observation time (from baseline) for the ulcer to occur 
or the observation time (from baseline) till the end of 
follow- up (ulcer- free survival). This is reported as HRs, 
which indicates the risk of ulceration.
Predicting the foot ulceration risk
Cox proportional hazard multiple regression analysis 
was used to find the minimum set of contributory factors 
that can predict the future diabetic foot ulceration occur-
rence with the highest prediction power.
To identify the effect of each set of parameters on the 
explanatory accuracy of the model, the covariates were 
A
U
TH
O
R 
PR
O
O
F
4 BMJ Open Diab Res Care 2020;0:e001122. doi:10.1136/bmjdrc-2019-001122
Pathophysiology/Complications
entered through consecutive blocks of covariates as 
shown in our previous study.29
In each block of parameters, an automated backward 
stepwise selection algorithm (retaining variables with 
p<0.05 removal testing is based on the probability of the 
Wald statistic) was used to arrive at the Cox proportional 
hazard multiple regression model. The collinearity between 
independent parameters in the same block was taken care 
of by the automated backward stepwise selection algorithm.
Cox proportional hazard multiple regression was also 
used to calculate HRs for each of the independent vari-
ables that stayed in the model. Chi- square and signifi-
cance level were used to indicate how worthwhile the 
model was in predicting the future ulceration. Further-
more, the area under the receiver operating character-
istic curve with 95% confidence level was calculated and 
referred to as the diagnosis strength of the model.
ResulTs
A total of 1810 (male (M)/female (F): 1012/798) patients 
with non- ulcerated feet were recruited and data were 
collected at the baseline. Then patients were followed 
for median of 133 days (range of 2904 days) until their 
first ulcer occurrence or until they were censored. One 
hundred and twenty- three patients (M/F: 68/55) ulcer-
ated and 1687 (M/F: 944/743) were ulcer free by the end 
of follow- up.
Tables 1–4 represent the results related to the categor-
ical and continuous parameters. Although there were no 
missing data for the categorical and for most of contin-
uous parameters. The missing data were accounted for in 
all statistical analyses, as indicated in tables 1–4.
Categorical parameters
Differences in categorical parameters between the groups with 
and without future ulcer incident
In comparing the categorical parameters between the 
two groups, it was found that neuropathy (χ2=26.46, 
Phi=0.123), history of ulceration (χ2=7.36, Phi=0.076), 
presence of callus (χ2=16.93, Phi=0.1), nail ingrowth 
(χ2=14.71, Phi=0.106), foot swelling (χ2=13.54, 
Phi=0.093), limited ankle (χ2=17.957, Phi=0.109), and 
metatarsophalangeal (MTP) joint (χ2=18.29, Phi=0.110) 
mobilities were all significantly (p<0.05) and with small 
effect size associated with incident of ulceration. Further-
more, insensitivity to touch (χ2=62.77, Cramer’s V=0.186) 
with medium effect size was significantly associated with 
future incident of ulceration.
Effect of categorical parameters on the risk and likelihood of DFU 
incident
The categorical parameters (HR (95% CI); OR (95% 
CI)) including neuropathy (2.525 (1.680 to 3.795); 2.926 
(1.926 to 4.444)); history of ulceration (2.796 (1.029 to 
7.598); 5.624 (1.738 to 18.198)); presence of callus (1.474 
(0.999 to 2.174); 2.361 (1.571 to 3.549)); nail ingrowth 
(5.653 (2.078 to 15.379); 11.308 (2.997 to 42.663)); foot 
swelling (3.345 (1.799 to 6.218); 3.667 (1.843 to 7.296)); 
dry skin (1.926 (1.273 to 2.914)); 2.344 (1.017 to 5.400)); 
limited ankle (1.662 (1.365 to 2.022); 2.552 (1.689 to 
3.856)) and MTP joint (2.745 (1.853 to 4.067); 2.527 
(1.673 to 3.818)) ranges of motion; and decreased (3.141 
(2.102 to 4.693); 3.723 (2.461 to 5.631)), highly decreased 
(5.263 (1.266 to 21.878); 6.967 (3.563 to 13.625)), and 
absent (9.671 (5.179 to 18.059); 7.340 (1.505 to 35.804)) 
sensation to touch were all significantly associated with 
higher risk and with higher likelihood of ulceration risk 
occurrence (tables 1 and 2). Furthermore, all patients 
with the characteristics described above showed signifi-
cantly decreased ulcer- free survival time compared with 
the patients without those characteristics (Kaplan- Meier 
survival analyses) (tables 1 and 2).
All categorical parameters (except history of smoking) 
which were significant risk factors for DFU occurrence 
were also significantly associated with the likelihood of 
DFU occurrence (tables 1 and 2).
History of smoking was the only parameter that showed 
to be significantly associated with risk (1.686 (1.097 to 
2.592)) of future DFU but was not significantly (p>0.05) 
associated with odds of ulceration occurrence and 
showed to significantly decrease the ulcer- free survival 
time by 324 days.
Continuous parameters
Differences in the continuous parameters between the group with 
and without future ulcer incident
While comparing the general continuous parameters 
between the two groups, the vulnerable group to future 
ulceration were significantly (p<0.05) older (U=89 544, 
Z=−2.53, r=0.06), had higher blood glucose level (U=91 
269, Z=−2.223, r=0.05), and showed lower plantar pres-
sure at the fifth toe (U=89 069, Z=−2.643, r=0.06) and 
lateral heel (U=90 531, Z=−2.363, r=0.06) regions during 
walking, all with small effect size, compared to their coun-
terparts who were non- vulnerable to future ulceration. 
The corresponding p values are shown in tables 3 and 4.
Mann- Whitney U test further revealed that the group 
who incurred DFU during follow- up had significantly 
(p<0.05) longer duration of diabetes (U=74 974, Z=−5.15, 
r=0.12); higher VPT at the foot (U=60 198, Z=−7.79, 
r=0.18), wrist (U=68 458, Z=−5.021, r=0.12), knee (U=58 
162, Z=−6.96, r=0.17), and ankle (U=54 774, Z=−7.615, 
r=0.18); higher TST (U=58 570, Z=−6.274, r=0.15) and 
TTT (U=55 662, Z=−6.799, r=0.16) to warm stimuli at 
their feet; lower TST (U=54 177, Z=−6.985, r=0.17) and 
TTT (U=61 673, Z=−5.624, r=0.14) to cold stimuli at their 
feet; all with small to medium effect size compared with 
the group that did not incur ulceration during follow- up. 
The corresponding p values are shown in table 3.
Effect of continuous parameters on the risk and likelihood of DFU 
incident
From the continuous parameters (HR (95% CI); OR 
(95% CI)): age (1.026 (1.010 to 1.042); 1.019 (1.003 to 
1.035)); VPT (1.079 (1.060 to 1.099); 1.073 (1.054 to 
1.092)); duration of diabetes in days (1.000 (1.000 to 
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Figure 1 The total risk (cumulative hazard) for diabetic foot ulcer incident as a function of follow- up time.
1.000); 1.000 (1.000 to 1.000)); TST (1.019 (1.004 to 
1.035); 1.031 (0.996 to 1.067)) and TTT (1.523 (1.337 to 
1.734); 1.517 (1.342 to 1.714)) to hot stimuli; and blood 
glucose level (1.027 (1.006 to 1.048); 1.024 (1.003 to 
1.045)) were all positively and significantly associated with 
increased risk (HR) and increase the likelihood (OR) of 
future foot ulcer occurrence (tables 3 and 4). However, 
plantar pressure underneath the fifth toe (0.990 (0.983 to 
0.998); 0.991 (0.983 to 0.998)) (table 4) and TST (0.755 
(0.688 to 0.829); 0.654 (0.565 to 0.757)) and TTT (0.668 
(0.592 to 0.0754); 0.717 (0.640 to 0.803)) to cold stimuli 
showed to significantly decrease both the risk (HR) and 
likelihood (OR) of the future DFU occurrence (table 3).
Most continuous parameters (except plantar pressure 
at the first MTH) which were significantly associated with 
the risk (based on univariate Cox regression) of DFU 
occurrence were observed to significantly increase the 
likelihood (based on univariate logistic regression) of 
DFU occurrence.
Plantar pressure at the first MTH showed to only signifi-
cantly increase the risk (HR= (1.003 (1.001 to 1.005)) 
but not the odds of the future DFU occurrence. On the 
other hand, there were only two continuous parameters 
including the plantar pressure at the lateral heel and ABI 
that showed to significantly decrease the likelihood (ORs 
(0.994 (0.989 to 1.000)) and (0.247 (0.073 to 0.834)), 
respectively, but not the hazard of future DFU occur-
rence (table 4).
The model to predict risk
Cox proportional hazard multiple regression analysis 
indicated a worthwhile model indicated by: χ2=94.545, 
p=0.000. The result of Cox proportional hazard 
multiple regression analysis indicated that only six (four 
categorical and two continuous) parameters stayed in 
the final risk prediction model. From those, only four 
parameters (two categorical and two continuous param-
eters) significantly contributed to predicting DFU risk 
(HR (95% CI)) as follows: nail ingrowth (4.42 (1.38 to 
14.07)); dry skin (4.48 (1.80 to 11.14)); VPT (1.07 (1.04 
to 1.09)); and TTT to warm stimuli (1.001 (1.000 to 
1.002)). Together with two other parameters that were 
not significant (p>0.05) predictors of DFU risk including 
neuropathy (1.13 (0.71 to 1.82)) and foot swelling 
(1.79 (0.91 to 3.52)), the overall model showed to be a 
worthwhile model (indicated by: χ2=94.545, p=0.000) to 
predict ulceration risk. The area below the ROC curve 
as a measure of prognosis power of the model was 0.62 
(0.57 to 0.67).
Figure 1 shows the cumulative hazard for DFU occur-
rence over time. This indicates how the risk of DFU 
increases over time. For example, the average risk of DFU 
is less than 0.1 (10%) at 1000 days follow- up. However, 
the risk increases to approximately 0.25 (25%) at 2000 
days follow- up.
For further information about the differences in the 
average survival times (ulcer- free time) for patients with 
dry skin, nail ingrowth, neuropathy, and swelling, the 
readers are referred to the supplementary materials 
(online supplementary appendices 1–4).
As in online supplementary appendix 2, the propor-
tion of population without ulcer at 2000 days follow- up 
was more than 0.8 in participants without neuropathy. 
However, this was just over 0.6 in participants with 
neuropathy. This indicates a significant decrease in the 
average ulcer- free survival as a result of neuropathy.
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dIsCussIOn
difference in parameters
The present study indicates that the patients with future 
DFU occurrence had distinctive characteristics in a set 
of parameters that were considered in this investigation. 
Significantly higher proportions of patients with any of 
the following characteristics: neuropathy, history of ulcer-
ation, presence of callus, nail ingrowth, foot swelling, and 
limited ankle and MTP joint mobilities were shown to 
have an incident of future DFU. However, the effect sizes 
were found to be small indicating that these criteria may 
not be used for effective patient stratification. On the 
other hand, we showed that a significantly higher propor-
tions of patients with impaired sensitivity to touch ended 
up having future incident of DFU. To be more precise, 
the higher the degree of impairment to touch, the higher 
the proportion of patients with DFU incident in that 
group. With a medium effect size, this indicates that this 
parameter has the potential for stratifying patients into 
four groups based on the sensitivity level to touch where 
each group showed a significantly higher prevalence of 
future DFU proportionate to the sensitivity level to touch 
sensation.
The significantly higher proportion of participants 
with impaired sensitivity to monofilament or history of 
ulcer incurred future DFU that is in line with the previous 
studies for neuropathy30 or for history of ulcer30–32 in 
European populations.
Out of all biomechanical parameters, limited ankle 
mobility that can indicate excessive load on the forefoot 
during ambulation was found to be significantly more 
prevalent in the group with future DFU occurrence that 
is in line with the results of the previous study in Europe.33
The results of this study highlighting the significantly 
older age and longer duration of diabetes of the group 
vulnerable to future DFU occurrence are in line with the 
previous finding for age in European31 and for the dura-
tion of diabetes in European30 31 and Middle Eastern34 
populations. This indicates similarities in the generic 
characteristics between the studied group and the patient 
population in previous studies.30 31 34
However, the results of the current study which indi-
cate that significantly higher proportion of patients who 
incur future DFU had callus or swollen feet contradicts 
the previous studies on south European population for 
callus30 31 or swollen foot30 31 where no such observations 
were reported.
These distinct differences in foot characteristics of 
patients with future DFU that were found in the current 
study can indicate a different etiology of ulceration in the 
studied group. In addition to the fact that the previous 
studies reported on a different demographic (ie, Euro-
pean30 vs African population in the current study), in few 
a combination of patients recruited from a hospital and 
a community setting was studied.30 However, our study 
which had a focus on patients in a hospital setting indi-
cates that with regards to identifying the patient group 
vulnerable to foot ulceration, attention need to be paid 
to patients with callus and swollen feet (edema).
Parameters associated with increased risk (hazard) and 
likelihood (odds) of dFu occurrence
The results of the current study in which association 
between older age and longer duration of diabetes on 
increasing the likelihood of DFU occurrence were found, 
are in line with the study conducted on the pooled 
patient data from Europe and North America.16 This can 
be the results of the deterioration in the soft tissue due to 
prolonged exposure to high blood sugar level, reflected 
in the significantly higher risk for future DFU occurrence 
for patients with higher duration of diabetes or higher 
blood glucose levels that were found in the current study. 
These reults of the current study are also in agreement 
with the findings from studies in North America.35 36 
Although the observed association between swollen feet 
and increased risk of future DFU occurrence in present 
study is in line with the findings of previous studies in 
North America,35 contrary to that study35 in the current 
study presence of callus was associated with increased risk 
of DFU occurrence.
On the other hand, onychomycosis was previously 
reported to have strong association with nail ingrowth37; 
hence, the results of the current study where nail 
ingrowth was associated with the future DFU occurrence 
are in agreement with a previous study on North Amer-
ican population.35
The significantly higher risk and more likelihood of 
future DFU occurrence for patients with impaired sensa-
tion to monofilament or with history of ulceration that 
is found in the present study are in line with the studies 
in North America35 36 or Europe16 indicating the notion 
that DFU occurrence is linked to the damages in the soft 
tissue which patient does not recognize as a result of 
impaired sensation. This can be further backed up by the 
result of the current study where a significantly higher 
likelihood of future DFU occurrence for patients with 
increased VPT was observed in accordance with previous 
study in Europe.38
Furthermore in line with other findings of the current 
study with regards to neuropathy, impaired sensation 
to touch21 showed significant association with future 
DFU occurrence in the present study. While the value 
of Ipswich touch test to accurately assess loss of protec-
tive sensation was previously established,39 the present 
study indicates that the risk of future DFU occurrence 
significantly increases as the level of impairment to touch 
sensation increases. Furthermore, the ulcer- free survival 
time also showed to significantly decrease as the sensi-
tivity to touch decreases. Hence, touch sense could be 
used to stratify patient based on the risk of future DFU 
occurrence.
The significant associations between impaired sensitiv-
ities and tolerances to temperature stimuli with the risk 
and likelihood of future DFU occurrence that observed 
in the present study indicate the importance of assessing 
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small fiber function in identifying the risk of future DFU 
and are in line with previous study on small cohort of 
patients.40
With regards to the biomechanical parameters, the 
association between limited MTP joint mobility and 
increased likelihood of future DFU occurrence is in line 
with the results of the previous findings in large cohorts 
from North America.14 This could be affiliated to the 
increased pressure on the forefoot that is observed as the 
significant association between the peak plantar pressure 
at the first MTH during shod walking and the DFU occur-
rence were reported in North American population.41
The fact that the ulcerated participants showed higher 
plantar pressure at the fifth MTH can be attributed to 
some morphological changes as a result of motor nerve 
damage in this group of patients where this leads to 
applying less load at the outer side of the forefoot. Inves-
tigating the motor neurons in patients with diabetes 
warrants further analyses in future studies.
While several categorical and continuous parameters 
were shown to increase the risk and likelihood of DFU 
in the current study, it can be argued that collecting all 
these parameters may not be feasible in a clinical setting. 
Hence, development of a model using proportionate 
hazard multiple regression analysis deemed necessary 
to reveal the minimum number of parameters which 
can predict the DFU with highest accuracy discussed as 
follows.
survival analysis (Cox regression model to identify ulcer-free 
survival)
The Cox regression model containing six parameters 
(including four categorical–out of which two were signifi-
cant predictors and two continuous–both were significant 
predictors) was found to be worthwhile for predicting 
the incident of diabetic foot ulceration.
Two categorical parameters, nail ingrowth and dry skin 
indicate that patients with each of these characteristics 
have significantly higher (four times more) risk of future 
ulcer occurrence compared with those without these 
characteristics.
In the present study, VPT was found to be a significant 
contributor to predicting the future DFU occurrence, 
and it indicates that increase in VPT by 1 V would increase 
the chance of ulceration by 7%.
Cox proportional hazard multiple regression analyses 
indicated that the final prediction model of foot ulcer-
ation included four significant (p<0.05) parameters, 
including: nail ingrowth, dry skin, VPT, and TTT to warm 
stimuli, plus the two non- significant (p>0.05), including 
neuropathy and foot swelling. The overall model showed 
to be a worthwhile model that can predict ulceration risk 
with a prognosis power of 0.62.
strength and limitations
The present study is unique as it reports on a wide range 
of foot- related parameters along with the clinical and life-
style characteristics to identify the risk factors for future 
DFU occurrence in large cohort of patients with diabetes 
in Africa. The prognosis power of the model proposed 
in the current study (0.62) is lower than the values of 
0.73 reported in other studies for western populations.31 
However in the current study when, a prognostic model 
was developed using only the three parameters (namely: 
absent pedal pulse, history of ulcer, and monofilament 
insensitivity) that were suggested based on a systematic 
review,16 the prognosis accuracy was found to be much 
lower.
Despite the difference in the prevalence of diabetic 
foot ulceration across African countries,7 it can be argued 
that there are similarities in ethnicity, socioeconomic 
conditions, and culture between Tanzania and Eastern, 
Central, and Western Africa. Hence, a similar model to 
the one that was developed in the current study may be 
applied to patients from those populations.
Clinical implications and future directions
The results of this study indicated that a few param-
eters significantly associated with and contributed to 
predicting the risk of DFU occurrence, except the nail 
ingrowth, the rest of parameters were related to neurop-
athy. This highlights the importance of considering both 
the sensory and autonomic peripheral neuropathy associ-
ated with large and small fiber impairment together.
The results on VPT (HR: 1.07) indicate the impor-
tance of assessing the impairment in A- alpha/beta as the 
nerves that are functional in sensing touch and vibration 
sensations.42 The impairment in C- fibers that is respon-
sible for input from high threshold stimuli43 44 indicated 
by the findings of the current study in which a high TTT 
to hot stimuli (HR: 1.001) are among the predictors of 
risk of future DFU occurrence. The results of the current 
study also indicated the importance of VPT and touch 
sensation in assessing the risk of DFU occurrence.
The impairment of small unmyelinated C- fibers of 
the peripheral nervous system that are responsible for 
cutaneous sensations and for mediating thermal sensa-
tions44 45 is reported in the current study, which is in line 
with the previous observations in patients with diabetic 
neuropathy and with DFU.15 46
The current study further indicates impairment of 
small fiber as mediator of autonomic functions such as 
sweating44 indicated by the importance of skin status (dry 
skin HR=4.48) in predicting the risk of future DFU occur-
rence. This is related to decreased activity of sweat glands 
and a dry skin,47 48 which make the dry skin vulnerable to 
cracks and fissures leading to ulceration.
Although previous studies indicate that the small fiber 
impairment precede large fiber complications in people 
with diabetes,48 the results of present study indicate that 
the measurements related to small fiber impairment 
provide as a strong prognostic tool to assess the risk of 
DFU occurrence.
Although in the current study a vast range of parame-
ters were collected from each participant, the inclusion of 
further parameters to reflect the microcirculatory49 and 
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mechanical properties of the plantar soft tissue50 could 
have resulted in achieving a higher prognosis power in 
predicting the DFU occurrence.
COnClusIOn
Participants who were vulnerable to future diabetic foot 
ulceration occurrence showed distinct characteristics in 
few foot- related parameters including higher VPT and 
lower sensitivity to touch, and lower sensitivity and higher 
tolerance to both warm and cold stimuli. The results of 
the current study indicate the need to assess small fiber 
neuropathy as a major risk factor for DFU occurrence 
in patients. The current study also highlighted that, the 
presence of nail ingrowth and dry skin each increase the 
likelihood of future DFU by more than four times.
In addition to the common measures of neuropathy 
associated with large fiber (ie, VPT and monofilament), 
measurements related to small fiber impairment (ie, TST 
and TTT; and touch sensation test) need to be included 
in the risk assessment for DFU occurrence.
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